Dr Durga Anil K Kanigicherla MBBS, MD, FRCP
Dr Durga Kanigicherla is a Consultant Nephrologist at Manchester University NHS Foundation Trust (MFT) with national leadership roles in immune-mediated kidney disease, transplantation, and medical education. He has been a Consultant since 2012 and holds an Honorary Senior Lectureship with the University of Manchester.
He is the Training Program Director for higher Specialty Training at NHS-NW, leads transplant recipient listing within the Nephrology Directorate, and is Associate Director of Medical Education at MFT, with strategic responsibility for the educational development of over 2,000 senior educators through the postgraduate education team. He has previously served as Deputy Clinical Director for Renal Medicine.
Dr Kanigicherla’s clinical and academic focus is immune kidney disease, glomerulonephritis, and kidney transplantation. He chairs the UK Membranous Nephropathy Rare Disease Group, contributed to the NHS CTE programme in membranous nephropathy, and is an active member of the Kidney Research UK Glomerulonephritis and Transplant Clinical Study Groups. His leadership contributed to Manchester Royal Infirmary being recognised as an ERKNet Expert Centre. He is Principal Investigator and Chief Investigator for multiple national and international clinical trials, and the Manchester Renal Biobank has been running successfully under his stewardship for over five years.
He was instrumental in establishing the Immune Kidney Network (IKNET), a national collaborative platform to improve sharing of best practice and innovation in immune kidney diseases, deliver year-round education with stakeholder support, and promote international partnerships. A strong advocate for innovation, Dr Kanigicherla is an AI enthusiast and is actively harnessing AI-enabled solutions to enhance clinical care, research delivery, and medical education.
He serves as a Trustee of Kidneys for Life and is committed to preventing progression to end-stage kidney disease, increasing access to transplantation as the preferred modality of renal replacement therapy, and improving long-term outcomes for patients.
ORCID: https://orcid.org/0000-0003-3011-7878